Everything below concerns responder analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Scotland was traditionally divided into four whisky regions: Campbeltown, The Highlands, The Isle of Islay and The Lowlands. Due to the large number of distilleries found there, the Speyside area became the fifth, recognised by the Scotch Whisky Association (SWA) as a distinct region in 2014. The whisky-producing islands other than Islay are not recognised as a distinct region by the SWA, which groups them into the Highlands region.
==== Accusations of Hezbollah using human shields ==== There have been claims that Hezbollah has intentionally drawn fire to Christian areas in southern Lebanon. Christians in the town of Rmaich clashed with Hezbollah due to the organization's attempts to establish military infrastructure in the town. The residents also wrote a complaint letter. On 26 March 2024, civilians in Rmaich confronted militants and rang their church bells after Hezbollah attempted to place rocket launchers in the town. Hezbollah denied trying to fire rockets from Rmaich. On 30 November 2024, the IDF said that it killed armed Hezbollah operatives near a church in southern Lebanon. A video appearing to be in the town of Khiyam, showed a tunnel shaft used to store weapons at the church. The Lebanese Kataeb Party criticized Hezbollah for allegedly storing weapons between houses stating that "Hiding weapons between houses does not support Gaza" after an IDF strike on Hezbollah infrastructure in Adloun. Rockets were still exploding about an hour after the strike was reported and the blasts lightly injured three citizens as shrapnel from the explosions flew to surrounding villages. These ammunition depots "open the door to Israeli attacks and turn the Lebanese into human shields", the Kataeb party said. According to IDF's Arabic spokesman, Avichay Adraee, Hezbollah-run yellow ambulances have been used to transport fighters and weapons.
Alexander Butlerov Institute of Chemistry trains students for school chemical Olympiads of the Republic of Tatarstan and the Russian Federation. At various times, professors of the Institute of Chemistry headed Russian teams at International School Chemistry Olympiad among them were Andrey N. Vedernikov, Arkady I. Kuramshin and Igor A. Sedov; The old building of the Alexander Butlerov Institute of Chemistry since it was built in 1953, was not only a laboratory building of chemical faculty of Kazan University, at different times, it also placed historical-philological faculty of Kazan University, military department, some rooms were used as a hostel for young teachers and graduate students of the University.
== Definition of stability, and naturally occurring nuclides == Most naturally occurring nuclides are stable (about 251; see list at the end of this article), and about 35 more (total of 286) are known to be radioactive with long enough half-lives (also known) to occur primordially. If the half-life of a nuclide is comparable to, or greater than, the Earth's age (4.5 billion years), a significant amount will have survived since the formation of the Solar System, and then is said to be primordial. It will then contribute in that way to the natural isotopic composition of a chemical element. Primordial radioisotopes are easily detected with half-lives as short as 700 million years (e.g., 235U). Shorter-lived nuclides have not yet been detected undisputedly in nature except when recently produced, such as decay products or cosmic ray spallation. Many naturally occurring radioisotopes (another 53 or so, for a total of about 339) exhibit still shorter half-lives than 700 million years, but they are made freshly, as daughter products of decay processes of primordial nuclides (for example, radium isotopes from uranium decay), or from ongoing energetic reactions, such as cosmogenic nuclides produced by present bombardment of Earth by cosmic rays (for example, 14C made from nitrogen). Some isotopes that are classed as stable (i.e. no radioactivity has been observed for them) are predicted to have extremely long half-lives (sometimes 1018 years or more).
Sources: en.wikipedia.org
However, deputy chief of Russia's General Staff Anatoliy Nogovitsyn disagreed with the notion that Russian use of force was "disproportionate". The European Union Special Representative for the South Caucasus, Peter Semneby, said, "It's not, obviously, the ultimate truth about the war". The BBC reported that "EU may welcome the report itself, but may want to distance itself from the content." A statement of the EU said that the report did not aim to pin the blame, but it could "contribute toward a better understanding of the origins and the course of last year's conflict". The British Foreign and Commonwealth Office spokesman urged "all sides to exercise restraint in their response to the report and redouble their efforts on working towards a durable and peaceful solution." Georgian State Minister for Reintegration Temur Iakobashvili disagreed that Georgia had used excessive force. He said that the report was mostly factual. Iakobashvili criticized the report's allegation that there was no massive Russian invasion because "There is no difference between the separatists and the Russian side". Secretary of the National Security Council of Georgia Eka Tkeshelashvili disputed the commission's statement that the first shot was fired by Georgia as erroneous assertion.
Current good manufacturing practices (cGMP) are those conforming to the guidelines recommended by relevant agencies. Those agencies control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use. The rules that govern each industry may differ significantly; however, the main purpose of GMP is always to prevent harm from occurring to the end user. Additional tenets include ensuring the end product is free from contamination, that it is consistent in its manufacture, that its manufacture has been well documented, that personnel are well trained, and that the product has been checked for quality more than just at the end phase. GMP is typically ensured through the effective use of a quality management system (QMS). Good manufacturing practice, along with good agricultural practice, good laboratory practice and good clinical practice, are overseen by regulatory agencies in the United Kingdom, United States, Canada, various European countries, China, India and other countries.
Histamine-mediated responses such as increased capillary permeability and vasodilation have been observed following intradermal administration of some opioids. However, nalbuphine does not elicit either a wheal or flare response, suggesting it does not promote histamine release from mast cells.
Sources: en.wikipedia.org
== Function == Bilirubin is created by the activity of biliverdin reductase on biliverdin, a green tetrapyrrolic bile pigment that is also a product of heme catabolism. Bilirubin, when oxidized, reverts to become biliverdin once again. This cycle, in addition to the demonstration of the potent antioxidant activity of bilirubin, has led to the hypothesis that bilirubin's main physiologic role is as a cellular antioxidant. Consistent with this, animal studies suggest that eliminating bilirubin results in endogenous oxidative stress. Bilirubin's antioxidant activity may be particularly important in the brain, where it prevents excitotoxicity and neuronal death by scavenging superoxide during N-methyl-D-aspartic acid neurotransmission.
== Regulation == The flux of the entire pathway is regulated by the rate-determining steps. These are the slowest steps in a network of reactions. The rate-limiting step occurs near the beginning of the pathway and is regulated by feedback inhibition, which ultimately controls the overall rate of the pathway. The metabolic pathway in the cell is regulated by covalent or non-covalent modifications. A covalent modification involves an addition or removal of a chemical bond, whereas a non-covalent modification (also known as allosteric regulation) is the binding of the regulator to the enzyme via hydrogen bonds, electrostatic interactions, and Van der Waals forces. The rate of turnover in a metabolic pathway, also known as the metabolic flux, is regulated based on the stoichiometric reaction model, the utilization rate of metabolites, and the translocation pace of molecules across the lipid bilayer. The regulation methods are based on experiments involving 13C-labeling, which is then analyzed by nuclear magnetic resonance (NMR) or gas chromatography–mass spectrometry (GC–MS)–derived mass compositions. The aforementioned techniques synthesize a statistical interpretation of mass distribution in proteinogenic amino acids to the catalytic activities of enzymes in a cell.
=== Metabolism === The alkaloids are organic nitrogenous compounds, derivatives of secondary metabolism, synthesised through the metabolic pathway of benzylisoquinoline. First, the amino acid phenylalanine, through the enzyme phenylalanine hydroxylase, is transformed into tyrosine. Tyrosine can follow two different routes: by tyrosine hydroxylase it can form L-dopamine (L-DOPA), or it can be reduced to form 4-phenylhydroxyacetaldehyde (4-HPAA). Subsequently, L-DOPA reacts with 4-HPAA and, through a series of reactions, forms (S) -norcoclaurine, which carries the benzylisoquinoline skeleton that gives its name to this pathway. The conversion of (S) -norcoclaurin to (S) -reticuline is one of the key points, since from (S) -reticuline morphine can be formed through the morphinan route, noscapine through the path of the noscapina or berberina.
=== Singapore === Singapore is an important hub for the passage of oil; it receives crude oil, mostly from the Middle East, and its refineries (most of which are on the 32-square-kilometre (12 sq mi) Jurong Island) produce the products which are then exported around the Asia-Pacific region, processing up to 1.5 million barrels of crude per day. Singapore and Australia made an agreement to keep their energy trade flowing, and Singapore economic officials have said that the country's refineries are maintaining stable operations and drawing on diverse supplies of crude oil.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.